Compare
Dyadic International Inc vs Humacyte, Inc. vs Zeo ScientifiX, Inc. vs Outlook Therapeutics, Inc.
| Latest fiscal year | Dyadic International Inc DYAI | Humacyte, Inc. HUMA | Zeo ScientifiX, Inc. ZEOX | Outlook Therapeutics, Inc. OTLK |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-10-31 | 2025-09-30 |
| Revenue | $3.09M | $2.04M | $5.20M | $1.41M |
| Revenue growth (YoY) | -11.6% | n/a | +12.5% | n/a |
| Gross margin | 24.9% (computed) | -376.1% (computed) | 82.1% | 4.0% |
| Operating margin | -232.8% | n/m | -103.6% | n/m |
| Net margin | -238.3% | n/m | -106.2% | n/m |
| Net income | -$7.36M | -$40.83M | -$5.52M | -$62.42M |
| EPS (Diluted) | -$0.23 | -$0.26 | -$0.86 | -$1.79 |
| Operating cash flow | -$5.70M | -$105.04M | -$718.0K | -$51.83M |
| Free cash flow | n/a | -$105.93M | -$741.0K | n/a |
| Cash & equivalents | $4.62M | $50.50M | n/a | $8.08M |
| Total assets | $9.95M | $116.37M | $1.53M | $18.58M |
| Total liabilities | $8.71M | $113.26M | $2.95M | $50.77M |
| Shareholders' equity | $1.23M | $3.11M | -$1.42M | -$32.19M |
| Return on year-end equity | -597.6% | n/m | n/a | n/a |
| Shares outstanding | 36.19M | 193.00M | 6.75M | 53.89M |
Revenue, most recent five fiscal years
| Fiscal year | Dyadic International Inc | Humacyte, Inc. | Zeo ScientifiX, Inc. | Outlook Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $3.09M Ended 2025-12-31 | $2.04M Ended 2025-12-31 | $5.20M Ended 2025-10-31 | $1.41M Ended 2025-09-30 |
| 1 year earlier | $3.50M Ended 2024-12-31 | $0 Ended 2024-12-31 | $4.62M Ended 2024-10-31 | n/a |
| 2 years earlier | $2.90M Ended 2023-12-31 | n/a | $4.56M Ended 2023-10-31 | n/a |
| 3 years earlier | $2.93M Ended 2022-12-31 | n/a | $6.49M Ended 2022-10-31 | n/a |
| 4 years earlier | $2.40M Ended 2021-12-31 | n/a | $5.60M Ended 2021-10-31 | n/a |